These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 22894957)

  • 1. Therapeutic vaccination to treat chronic infectious diseases: current clinical developments using MVA-based vaccines.
    Boukhebza H; Bellon N; Limacher JM; Inchauspé G
    Hum Vaccin Immunother; 2012 Dec; 8(12):1746-57. PubMed ID: 22894957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical applications of attenuated MVA poxvirus strain.
    Gómez CE; Perdiguero B; García-Arriaza J; Esteban M
    Expert Rev Vaccines; 2013 Dec; 12(12):1395-416. PubMed ID: 24168097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development.
    Volz A; Sutter G
    Adv Virus Res; 2017; 97():187-243. PubMed ID: 28057259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Attenuated poxvirus vectors MVA and NYVAC as promising vaccine candidates against HIV/AIDS.
    Esteban M
    Hum Vaccin; 2009 Dec; 5(12):867-71. PubMed ID: 19786840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective efficacy of Modified Vaccinia virus Ankara in preclinical studies.
    Volz A; Sutter G
    Vaccine; 2013 Sep; 31(39):4235-40. PubMed ID: 23523402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical development of Modified Vaccinia virus Ankara vaccines.
    Gilbert SC
    Vaccine; 2013 Sep; 31(39):4241-6. PubMed ID: 23523410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery.
    Sutter G; Staib C
    Curr Drug Targets Infect Disord; 2003 Sep; 3(3):263-71. PubMed ID: 14529359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant MVA vaccines: dispelling the myths.
    Cottingham MG; Carroll MW
    Vaccine; 2013 Sep; 31(39):4247-51. PubMed ID: 23523407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New viral vectors for infectious diseases and cancer.
    Sasso E; D'Alise AM; Zambrano N; Scarselli E; Folgori A; Nicosia A
    Semin Immunol; 2020 Aug; 50():101430. PubMed ID: 33262065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Highly Attenuated Poxvirus-Based Vaccines Against Emerging Viral Diseases.
    Perdiguero B; Pérez P; Marcos-Villar L; Albericio G; Astorgano D; Álvarez E; Sin L; Gómez CE; García-Arriaza J; Esteban M
    J Mol Biol; 2023 Aug; 435(15):168173. PubMed ID: 37301278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies.
    Garber DA; O'Mara LA; Zhao J; Gangadhara S; An I; Feinberg MB
    PLoS One; 2009; 4(5):e5445. PubMed ID: 19421328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preferential Targeting of Conserved Gag Regions after Vaccination with a Heterologous DNA Prime-Modified Vaccinia Virus Ankara Boost HIV-1 Vaccine Regimen.
    Bauer A; Podola L; Mann P; Missanga M; Haule A; Sudi L; Nilsson C; Kaluwa B; Lueer C; Mwakatima M; Munseri PJ; Maboko L; Robb ML; Tovanabutra S; Kijak G; Marovich M; McCormack S; Joseph S; Lyamuya E; Wahren B; Sandström E; Biberfeld G; Hoelscher M; Bakari M; Kroidl A; Geldmacher C
    J Virol; 2017 Sep; 91(18):. PubMed ID: 28701395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. E3L and F1L Gene Functions Modulate the Protective Capacity of Modified Vaccinia Virus Ankara Immunization in Murine Model of Human Smallpox.
    Volz A; Jany S; Freudenstein A; Lantermann M; Ludwig H; Sutter G
    Viruses; 2018 Jan; 10(1):. PubMed ID: 29300297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poxviral promoters for improving the immunogenicity of MVA delivered vaccines.
    Alharbi NK
    Hum Vaccin Immunother; 2019; 15(1):203-209. PubMed ID: 30148692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral vaccination with modified vaccinia virus Ankara attached covalently to TMPEG-modified cationic liposomes overcomes pre-existing poxvirus immunity from recombinant vaccinia immunization.
    Naito T; Kaneko Y; Kozbor D
    J Gen Virol; 2007 Jan; 88(Pt 1):61-70. PubMed ID: 17170437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent Anti-hepatitis C Virus (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-Launched RNA Replicons and Modified Vaccinia Virus Ankara-HCV.
    Marín MQ; Pérez P; Ljungberg K; Sorzano CÓS; Gómez CE; Liljeström P; Esteban M; García-Arriaza J
    J Virol; 2019 Apr; 93(7):. PubMed ID: 30674625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox.
    Pittman PR; Hahn M; Lee HS; Koca C; Samy N; Schmidt D; Hornung J; Weidenthaler H; Heery CR; Meyer TPH; Silbernagl G; Maclennan J; Chaplin P
    N Engl J Med; 2019 Nov; 381(20):1897-1908. PubMed ID: 31722150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MVA E2 recombinant vaccine in the treatment of human papillomavirus infection in men presenting intraurethral flat condyloma: a phase I/II study.
    Albarran Y Carvajal A; de la Garza A; Cruz Quiroz BJ; Vazquez Zea E; Díaz Estrada I; Mendez Fuentez E; López Contreras M; Andrade-Manzano A; Padilla S; Varela AR; Rosales R
    BioDrugs; 2007; 21(1):47-59. PubMed ID: 17263589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial.
    Kreijtz JH; Goeijenbier M; Moesker FM; van den Dries L; Goeijenbier S; De Gruyter HL; Lehmann MH; Mutsert Gd; van de Vijver DA; Volz A; Fouchier RA; van Gorp EC; Rimmelzwaan GF; Sutter G; Osterhaus AD
    Lancet Infect Dis; 2014 Dec; 14(12):1196-207. PubMed ID: 25455987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1.
    Mothe B; Climent N; Plana M; Rosàs M; Jiménez JL; Muñoz-Fernández MÁ; Puertas MC; Carrillo J; Gonzalez N; León A; Pich J; Arnaiz JA; Gatell JM; Clotet B; Blanco J; Alcamí J; Martinez-Picado J; Alvarez-Fernández C; Sánchez-Palomino S; Guardo AC; Peña J; Benito JM; Rallón N; Gómez CE; Perdiguero B; García-Arriaza J; Esteban M; López Bernaldo de Quirós JC; Brander C; García F;
    J Antimicrob Chemother; 2015; 70(6):1833-42. PubMed ID: 25724985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.